Abstract
Purpose
To compare the efficacy and safety of two combinations of maximum medical therapy for lowering intraocular pressure (IOP) in primary open angle glaucoma (POAG).
Study design
A retrospective consecutive case series.
Methods
A retrospective consecutive case series study including 82 eyes of 82 subjects with POAG treated with maximum medical therapy to lower IOP. Enrolled patients were divided into 2 groups: the triple maximum medical therapy (TMT) group, comprising POAG patients who were treated with tafluprost, brimonidine and the fixed drug combination (FDC) brinzolamide/timolol; and the double maximum medical therapy (DMT) group, comprising POAG patients who were treated with the FDCs tafluprost/timolol and brinzolamide/brimonidine. We compared the demographics, baseline IOP, IOP reduction rate, and adverse drug reactions (ADRs) between the 2 groups.
Results
While the mean IOP reduction rate after 12 months was higher in the TMT group (52.7%) than in the DMT group (50.4%), the difference was not significant (p-value = 0.615). In the TMT group, the rate of proceeding to laser or surgical therapy was 22.2% (DMT group = 37.8%). In the TMT group, the time duration between beginning maximum medical therapy and proceeding to laser or surgical therapy was 10.7 ± 1.3 months (DMT group = 10.3 ± 1.5 months). No serious ADRs were reported in either group. However, the incidence rate of conjunctival hyperemia and dry eye was significantly lower in the DMT group than in the TMT group.
Conclusion
DMT is safe and effective for lowering IOP in POAG patients. DMT is not inferior to TMT in POAG patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
European Glaucoma Society. Terminology and guidelines for glaucoma, 4th edition, http://bjo.bmj.com/content/bjophthalmol/101/4/1.full.pdf.
American Academy of Ophthalmology Glaucoma Panel. Preferred practice pattern guidelines. Primary open angle glaucoma. San Francisco: American Academy of Ophthalmology; 2010.
Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008;25:729–59.
Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994;112:644–9.
Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, et al. The ocular hyperten-sion treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.
Inoue K, Ishida K, Tomita G. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Jpn J Ophthalmol. 2018;62:508–16.
Komizo T, Ono T, Yagi A, Miyata K, Aihara M. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma. Jpn J Ophthalmol. 2019;63:40–5.
Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Opththalmol. 2008;53(Suppl 1):S57–68.
Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1–7.
Lee AJ, McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol. 2008;2:545–55.
Inoue K, Shiokawa M, Sugahara M, Wakakura M, Soeda S, Tomita G. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol. 2012;56:559–63.
Tham CC, Kwong YY, Leung DY, Lam SW, Li FC, Chiu TY, et al. Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. Ophthalmology. 2009;116:725–31.
Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900–7.
The DEWS Definition and Classification Subcommittee. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5:75–92.
Holló G, Hommer A, Antón López A, Ropo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30:468–75.
Inoue K, Kawashima T, Katakura S, Shidara K, Fujimoto T, Kohmoto H, et al. Switching from concomitant therapy to tafluprost/timolol fixed combination. Clin Ophthalmol. 2018;12:549–54.
Jin SW, Lee SM. The efficacy and safety of the fixed combination of brinzolamide 1% and brimonidine 02% in normal tension glaucoma: an 18-month retrospective study. J Ocul Pharmacol Ther. 2018;34:274–9.
Acknowledgements
This work was supported by Dong-A University Research Fund. The authors thank American Journal Experts (http://www.journalexperts.com) for providing editing services for this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
H. J. Joh, None; S. W. Jin, None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Corresponding author: Sang Wook Jin
About this article
Cite this article
Joh, H.J., Jin, S.W. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series. Jpn J Ophthalmol 63, 322–327 (2019). https://doi.org/10.1007/s10384-019-00673-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-019-00673-8